Clexane is a low molecular weight heparin with anticoagulant properties. It enhances the inhibition rate of clotting factors in blood thereby preventing the formation of unwanted blood clots in blood vessels. It can also stop any blood clots that have already formed from growing bigger. Clexane does not break down blood clots that have already formed.
Clexane cannot be taken by mouth, or given through an intravenous drip. It is given by an injection under the skin.
Clexane is available in strengths of 20 mg, 40 mg, 60 mg and 80 mg and is used in following indications:
Prophylaxis of venous thromboembolism during surgical procedures
Deep vein thrombosis
Prophylaxis of clotting in the extracorporeal circulation during haemodialysis
Clexane is a brand of Sanofi, a global healthcare leader with presence in more than 170 countries globally and nearly 79 manufacturing sites in 36 countries. Sanofi is an innovator of many life-saving drugs. As a health journey partner, Sanofi focuses on improving quality of life of patients. In 2016, Sanofi partnered with Verily to found Onduo, a joint-venture focusing on holistic solutions to improve diabetes management globally.
Enoxaparin is a low molecular weight heparin. It is used to prevent and treat deep vein thrombosis (clots) or pulmonary embolism, and is given as a subcutaneous injection. Enoxaparin binds to and accelerates the activity of its cofactor, the antithrombin III. By activating antithrombin III, enoxaparin inhibits the coagulation factors. Inhibition of this coagulation factors results in decreased clot formation.
Enoxaparin is used to prevent deep vein thrombosis, which may lead to pulmonary embolism (clot in lungs). It is also used in the management of unstable angina and specific type of heart attack, when concurrently administered with aspirin.
Enoxaparin acts at multiple sites in the normal coagulation system. Once active thrombosis (clot) has developed, administration of enoxaparin can inhibit further coagulation. Enoxaparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.
Those undergoing Coronary Angioplasty have an increased risk of clot formation within the stent after the procedure that can be dangerous. To reduce this risk enoxaparin is administered to patient patients undergoing Coronary Angioplasty
As directed by your Physician
As directed by your Physician
Adverse Reactions/ Side Effects
Haemorrhage (including at the injection site), peripheral or unspecified oedema, anaemia, haematuria, ecchymosis, fever, confusion, nausea, diarrhoea, dyspnoea, injection site pain.
Potentially Fatal: Major haemorrhagic complications (e.g. retroperitoneal and intracranial bleeding).
Warnings and Precautions
Patients w/ low body weight (women: <45 kg; men: <57 kg), bleeding diathesis, diabetic retinopathy, history of recent GI ulceration, history of heparin-induced thrombocytopenia, uncontrolled arterial HTN, or haemorrhage. Hepatic and renal impairment. Elderly, pregnancy and lactation. Monitoring Parameters Monitor patients for signs and symptoms of neurological impairment during treatment or immediately following diagnostic lumbar puncture, spinal or epidural anaesthesia. Periodic monitoring of CBC (e.g. platelet counts, stool occult blood tests). Monitor vascular access sites for signs of bleeding or haematoma during treatment.
Hypersensitivity to enoxaparin, heparin. Patients w/ active major bleeding, acute bacterial endocarditis, recent haemorrhagic stroke, active gastric or duodenal ulceration, thrombocytopenia associated w/ positive in vitro test for platelet antibodies.
Increased risk of bleeding w/ anticoagulants, platelet aggregation inhibitors (e.g. dipyridamole, salicylates, NSAIDs, sulfinpyrazone). May increase bleeding w/ vit E.
Symptoms: Haemorrhagic complications.
Management: Admin of protamine by slow IV injection.
Parenteral: Store at 25°C.
Subcutaneous: Store at 25°C.
Mechanism of Action
Enoxaparin is a low molecular weight heparin w/ anticoagulant properties. It acts by enhancing the inhibition rate of activated clotting factors including thrombin and factor Xa through its action on antithrombin III.